FDA Grants Accelerated Review For Pfizer Cancer Drug – Automated Trader

by lowes1 on May 17, 2011

FDA Grants Accelerated Review For Pfizer Cancer Drug
Automated Trader
The fusion of ALK with another gene is believed to be present in about 3% to 5% of people with non-small cell lung cancer, or 40000 patients diagnosed annually worldwide. Pfizer has proposed to market the drug for the treatment of ALK-positive advanced
Pfizer Files NDA For Lung Cancer Drug Crizotinib With FDA, Japan – UpdateRTT News
Pfizer's Application for Cancer Drug Accepted by FDAWall Street Journal
Pfizer cancer drug takes big step toward fateful FDA decisionFierceBiotech
Forbes -MyStateline.com -Xconomy
all 29 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: